Does doxepin increase heart rate?

Does Doxepin Increase Heart Rate?

Yes, doxepin does increase heart rate. This is a well-documented cardiovascular effect of this tricyclic antidepressant, though the increase is typically modest and clinically manageable in most patients.

Evidence from FDA Drug Labeling

The FDA-approved prescribing information does not explicitly list tachycardia as a primary adverse effect in the main warnings, but the drug's mechanism provides important context. Doxepin influences adrenergic activity at synapses by preventing norepinephrine reuptake, which can lead to increased sympathetic tone 1.

Clinical Research Findings

Magnitude of Heart Rate Increase

Research demonstrates that doxepin produces small but statistically significant increases in heart rate:

• In elderly depressed patients, doxepin caused small but significant increases in heart rate along with prolonged PR intervals 2
• A comparative study showed doxepin increased heart rate by approximately 5 beats per minute, which was less than amitriptyline's 10 beats per minute increase 3
• In cardiac patients with ventricular arrhythmias, doxepin increased heart rate, though this was not the primary concern (sedation was the dose-limiting factor) 4
• A study in healthy subjects showed a slight increase of 2-6 beats per minute on exertion, most marked in younger patients, but this was neither clinically nor statistically significant 5

Mechanism

The heart rate increase is attributed to the "cocaine-like effect" of tricyclic psychotropic drugs 5, related to their anticholinergic properties and norepinephrine reuptake inhibition.

Clinical Context and Risk Stratification

When to Exercise Caution

Tricyclic antidepressants as a class carry cardiac risks, particularly:

• QT interval prolongation
• Increased risk of cardiac arrest (OR 1.69 for TCAs) 6
• AV node conduction delays potentially leading to AV block 6
• Risk increases with dose and in elderly patients

Relative Safety Profile

Despite the heart rate increase, doxepin appears relatively safer than some other TCAs:

• Less tachycardic than amitriptyline (5 vs 10 bpm increase) 3
• At doses around 75 mg/day for moderate duration, no cardiotoxic side effects were observed in controlled studies 5
• In elderly cardiac patients with stable angina or old MI, neither doxepin nor maprotiline produced untoward effects 2

Practical Recommendations

Baseline Assessment

Before initiating doxepin, obtain:

• Baseline ECG in patients with cardiac risk factors, elderly patients, or those on doses that may be escalated
• Assessment for pre-existing conduction abnormalities
• History of arrhythmias or structural heart disease

Monitoring Strategy

• Monitor heart rate at baseline and after dose adjustments
• Expect a modest increase of 5-10 bpm, particularly in younger patients
• Consider ECG monitoring if:
  • Doses exceed 150 mg/day
  • Patient has pre-existing cardiac disease
  • Patient is elderly (>60 years)
  • Concurrent use of other QT-prolonging medications

Dose Considerations

• Low doses (3-6 mg) for insomnia appear to have minimal cardiovascular effects 7, 8
• Higher antidepressant doses (75-150 mg) produce more noticeable but generally tolerable heart rate increases 5
• The heart rate increase is dose-dependent but typically not clinically significant in patients without underlying cardiac disease

Key Caveats

• The heart rate increase is generally mild and well-tolerated in most patients
• Sedation, not tachycardia, is typically the dose-limiting side effect 4
• Greater concern should be directed toward QT prolongation and conduction delays rather than simple heart rate elevation
• In patients with heart block or intracardiac conduction delays, doxepin may actually be preferable to some other TCAs due to its effect on QRS interval 2